Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®)) Alone and in Combination With Epoetin Alfa (Procrit®)) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Brief Summary: This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.


Options:
A: Arm Label: EPO plus sustained iron dextran; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietins (EPO), Drug: Sustained iron dextran supplementation | Arm Label: EPO plus aggressive iron dextran; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietins (EPO), Drug: Aggressive iron dextran supplementation | Arm Label: Double EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietins (EPO) | Intervention Type: DRUG; Name: Erythropoietins (EPO); Assigned to Arm(s): EPO plus aggressive iron dextran, EPO plus sustained iron dextran | Intervention Type: DRUG; Name: Aggressive iron dextran supplementation; Assigned to Arm(s): EPO plus aggressive iron dextran | Intervention Type: DRUG; Name: Erythropoietins (EPO); Assigned to Arm(s): Double EPO | Intervention Type: DRUG; Name: Sustained iron dextran supplementation; Assigned to Arm(s): EPO plus sustained iron dextran
B: Arm Label: Intravenous iron; Type: EXPERIMENTAL; Interventions: Drug: Intravenous iron | Arm Label: Oral iron; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous iron | Intervention Type: DRUG; Name: Intravenous iron; Assigned to Arm(s): Intravenous iron, Oral iron
C: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Arm A (lenalidomide); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bone Marrow Biopsy, Other: Laboratory Biomarker Analysis, Drug: Lenalidomide | Arm Label: Arm B (lenalidomide, epoetin alfa); Type: EXPERIMENTAL; Interventions: Procedure: Bone Marrow Biopsy, Biological: Epoetin Alfa, Other: Laboratory Biomarker Analysis, Drug: Lenalidomide | Intervention Type: PROCEDURE; Name: Bone Marrow Biopsy; Assigned to Arm(s): Arm A (lenalidomide), Arm B (lenalidomide, epoetin alfa) | Intervention Type: BIOLOGICAL; Name: Epoetin Alfa; Assigned to Arm(s): Arm B (lenalidomide, epoetin alfa) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (lenalidomide), Arm B (lenalidomide, epoetin alfa) | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Arm A (lenalidomide), Arm B (lenalidomide, epoetin alfa)

Answer: D